The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer, according to interim data from the dose-expansion portion of the phase 1 STRO-002-GM1 trial (NCT03748186).1 As of the interim data cutoff date of November 8, 2021, the ADC produced an objective response rate (ORR) of […]

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. In this interview, CEO Paul Wotton discusses the applications of Obsidian’s cytoDrive technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy. Please describe the story behind the company: What sparked the idea, and […]

After a decade of breakthroughs in biopharma, highlighted by the development of a vaccine against the novel coronavirus in just nine months, expectations of 2022 couldn’t be higher. From a continued focus on oncology and the resurgence of risk appetite in neuroscience, many expect a rebound for the life sciences capital markets paired with a year […]